Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on March 5, 2025, covering the earliest event date of March 3, 2025. The filing addresses a change in the composition of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statement data.
Material Changes
The material change reported is the departure of a director:
- Phillip A. Sharp, Ph.D. informed the Board of his retirement, effective May 8, 2025.
- The retirement is not due to any disagreement with the Company regarding operations, policies, or practices.
- Dr. Sharp will continue to serve as a member of the Company's Scientific Advisory Board following his retirement from the Board.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, outlook, management commentary on business performance, or new risk factors. The only contingency noted is the scheduled transition of Dr. Sharp's role from the Board to the Scientific Advisory Board.
Investor Verification Checklist
- Confirm the effective date of Dr. Sharp's retirement (May 8, 2025).
- Verify the appointment of any new director to fill the vacancy on the Board.
- Review the press release (Exhibit 99.1) for additional details on Dr. Sharp's future role on the Scientific Advisory Board.